Nuvation Bio Inc Cash Flow Conversion Efficiency
Nuvation Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Nuvation Bio Inc (NUVB) has a cash flow conversion efficiency ratio of -0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.07 Million) by net assets ($253.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Nuvation Bio Inc (2018–2025)
Cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2025. This chart illustrates how Nuvation Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Nuvation Bio Inc for real-time trading data and today's change.
Nuvation Bio Inc Cash Flow Conversion Ratio Explained
Nuvation Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Nuvation Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nuvation Bio Inc ranked by their cash flow conversion efficiency. Also see how much is Nuvation Bio Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mullen Group Ltd.
TO:MTL
|
0.052x |
|
Xianhe Co Ltd
SHG:603733
|
0.080x |
|
Paradox Interactive AB (publ)
ST:PDX
|
0.119x |
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
0.069x |
|
Zhejiang Expressway Co. Ltd
F:ZHJ
|
0.012x |
|
A.F.P. Provida
SN:PROVIDA
|
0.022x |
|
Ardent Health Partners, Inc.
NYSE:ARDT
|
0.078x |
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
0.001x |
Annual Cash Flow Conversion Efficiency for Nuvation Bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Nuvation Bio Inc from 2018 to 2025. Review Nuvation Bio Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.72 Million | $-173.43 Million | -0.567x | -101.74% |
| 2024-12-31 | $463.79 Million | $-130.41 Million | -0.281x | -150.23% |
| 2023-12-31 | $605.12 Million | $-68.00 Million | -0.112x | +23.41% |
| 2022-12-31 | $655.08 Million | $-96.11 Million | -0.147x | -60.50% |
| 2021-12-31 | $746.00 Million | $-68.19 Million | -0.091x | +46.18% |
| 2020-12-31 | $215.08 Million | $-36.53 Million | -0.170x | +18.15% |
| 2019-12-31 | $117.75 Million | $-24.43 Million | -0.207x | -125.06% |
| 2018-12-31 | $-744.00K | $-616.00K | 0.828x | -- |
About Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the ma… Read more